TruScreen provides an accurate, real-time screening solution. Our primary screening solution is ideal for communities that cannot access conventional, laboratory dependant, screening methods. It is affordable and easy to learn.
Our purpose is to ensure that all women of screening age, no matter who or where they are, have access to quality screening.
What is TruScreen?
Established in 2013, TruScreen has been working towards its vision of A World Without Cervical Cancer.Our People
Our market potential is huge with over a billion women eligible for screening in our key markets.TruScreen's Markets
WHO estimates that in 2020, there was 600,000+ new cases of cervical cancer worldwide.Learn more about Cervical Cancer
The TruScreen device has been clinically validated on over 40,000 women in multiple settings.*MORE DATA
Associate Professor Michael J. Campion, TruScreen Medical Advisory Committee Chairman, sits down to discuss the science behind TruScreen’s Device, its clinical validation, and its application in real-world settings.
“My main clinical interest has been in the prevention of cervical cancer…it’s an amazing reality that perhaps the best of the biophysical screening tools, certainly for cervical cancer, has been developed entirely in Australia.”Watch Video
In low- and middle-income countries (LMICs) cervical cancer is the second most common form of cancer among women. About 90% of deaths from cervical cancer occur in LMICs.
The TruScreen device offers an alternative approach to cervical screening, resolving many of the ongoing issues with conventional screening methods, including accessibility and the need for supporting laboratory infrastructure.Learn more
Market research company, Pitt Street, released its updated report on TruScreen.View
The Zimbabwe National AIDS Council (NAC) wrapped up its current TruScreen pilot program in January. 10,000+ women were screened during the 6-month pilot. For many of these women this isView
At the end of 2022, TruScreen’s Mexican distributor in conjunction with a local foundation brought TruScreen screening to vulnerable young women.View
TruScreen’s Commercial GM travelled to Vietnam in late 2022 as boarders reopen and pandemic pressures begin to ease.View
NZX/ASX Announcement 15 December 2021 TruScreen Group Limited (NZX/ASX: TRU) (‘TruScreen’ or ‘the Company’) is pleased to provide a market update, outlining the Company’s progress in several of its keyView
Cervical cancer is one of the most preventable and treatable forms of cancer, yet over a quarter of a million women die from the disease each year. Ninety percent ofView
Zimbabwe may be known for its pristine wilderness, but it is also a country facing a major public health crisis in the form of high HIV and cervical cancer rates.View
Cervical cancer technology company, TruScreen Limited (NZAX:TRU), announces that its newly commissioned facility to manufacture the diagnostic Opto-electric front-end component of its device in Australia, is now fully operational.View
Dr. Carolina Velasquez traveled to Vietnam to conduct clinical training and launch the TruScreen Pilot Study, being conducted out of Hanoi Gynaecology and Obstetrics Hospital. The Pilot Study, being overseenView
Our Russian distributor IntelMed Systems takes us into local hospitals where TruScreen pilot programmes are underway.View
Despite its rapidly growing economy, China remains a low- and middle-income nation. An example of this is its healthcare system. Although China has made impressive strides in improving healthcare accessView
Truscreen Group Limited (NZX/ASX: TRU) is pleased to provide a copy of its August 2021 Stakeholders Newsletter. This gives an update on TruScreen's performance and highlights key initiatives underway. HighlightsView
As announced last month, TruScreen's cervical cancer screening device was recognised in a joint publication that Unitaid has released with the World Health Organisation and the Clinton Health Access Initiative.View
TruScreen Group Limited is pleased to advise that it has received its first order from Serbia, Eastern Europe.View
Cervical cancer is the fourth most common cancer in women, with more than half a million women diagnosed with the disease in 2018. In low- and middle-income countries (LMIC’s) cervicalView
In September 2021, TruScreen’s Russian distributor, Intelmed Systems, participated in the 15th annual “Wave of Health” initiative. The annual “Wave of Health” campaign sees a ship with teams of doctorsView
Cervical cancer affects millions of women worldwide. It is a silent killer, it has a high prevalence outside of developed countries, and almost all cases of cervical cancer can beView
TruScreen’s breakthrough cervical cancer screening device is a viable and attractive alternative to traditional cervical screening methods. The TruScreen device resolves many of the ongoing issues associated with Pap tests,View
Associate Professor Michael J. Campion, TruScreen Medical Advisory Committee member, sits down to discuss the science behind TruScreen’s Cervical Cancer Screening Device, its clinical validation, and its application in real-worldView
The National Aids Council pilot will compare TruScreen to VIAC. VIAC is currently the common screening method for cervical cancer in the region. The NAC pilot hopes to have TruScreenView
A new study, published in the European Journal of Obstetrics and Gynaecology and Reproductive Biology, concludes that TruScreen’s cervical cancer screening technology meets or exceeds the effectiveness of alternative cervicalView
TruScreen Group Limited is pleased to announce the achievement of key milestones relating to the ongoing development of the Company’s women’s health care technology and its overseas growth strategy.View
ASX Article | Wed 08 February 2023 | Tony Featherstone Move turns spotlight on medtech’s cervical-cancer screening device.View